Data management and governance efficiencies were at the center of AstraZeneca’s accelerated transition to an omnichannel strategy in a bid to boost engagements with healthcare professionals (HCPs).

CGTs are often expensive, and the healthcare sector is increasingly working on a tight budget. To bolster CGT market access potential, pharma companies should take a holistic approach.

Although cell and gene therapies (CGTs) are typically expensive products, there are techniques that pharmaceutical companies can execute to underscore why they are worthwhile.

Clinical trial sponsors should implement multiple approaches to boost diversity in studies, from ensuring collected data reflect participant diversity, to working with a diverse group of investigators